Under construction – not a live service

Skip to content

Frontlight Research

Institution

Moffitt Cancer Center

Tampa, United StatesWebsite

Also known as: H. Lee Moffitt Cancer Center & Research Institute · H. Lee Moffitt Cancer Center and Research Institute · Moffitt Cancer Center & Research Institute · Moffitt Cancer Center and Research Institute · Moffitt Cancer Center at Tampa General Hospital

532running trials
204closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

No trial has been confirmed here yet.

Running trials

Not yet recruiting
Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
NCT07101666· Phase 2· Source
Not yet recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895· Phase 1/2· Source
Recruiting
Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring
NCT07930182· Phase 2· Source
Not yet recruiting
Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC
NCT07870746· Phase 2· Source
Recruiting
A Study of DS-3939a in Participants With Solid Tumors
NCT07739966· Phase 1/2· Source
Recruiting
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
NCT07741877· Phase 2· Source
Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Source
Recruiting
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
NCT07805954· Phase 3· Source
Recruiting
Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors
NCT07487168· Phase 1· Source
Recruiting
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
NCT07779798· Phase 1· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795· Phase 2· Source
Recruiting
Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma
NCT07725380· Phase 1/2· Source
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT07365241· Phase 3· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002· Phase 2/3· Source
Recruiting
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
NCT07012031· Phase 1/2· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559· Phase 2· Source
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820· Phase 2· Source
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960· Phase 1/2· Source
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206· Phase 3· Source
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718· Phase 3· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Source
Recruiting
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
NCT07278479· Phase 1/2· Source
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694· Phase 1· Source
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566· Phase 2· Source
Not yet recruiting
The Canopy Cancer Collective Clinical Registry Protocol
NCT07605702· Source
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322· Phase 2· Source
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891· Phase 1· Source
Recruiting
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT07458347· Phase 1· Source
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095· Phase 1· Source
Recruiting
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
NCT07464925· Phase 1· Source
Recruiting
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
NCT07542041· Source
Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
NCT07544589· Phase 1· Source
Recruiting
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
NCT07144319· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Source
Recruiting
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413· Phase 1· Source
Recruiting
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
NCT07476001· Phase 2· Source
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246· Phase 1· Source
Recruiting
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
NCT07357298· Phase 3· Source
Recruiting
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
NCT07194044· Phase 1· Source
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· Phase 1/2· Source
Recruiting
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177· Phase 2· Source
Recruiting
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
NCT06875128· Phase 2· Source
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231· Phase 3· Source
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778· Phase 2· Source
Recruiting
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
NCT07250087· Phase 1· Source
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558· Phase 3· Source
Recruiting
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
NCT07033598· Phase 2· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Source
Recruiting
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
NCT07276386· Phase 2· Source

Showing 50 of 532.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

Closed trials

Withdrawn
Wet Heparinized Suction for Abdominal Cancer
NCT05041335· Source
Terminated
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
NCT06704152· Phase 1/2· Source
Completed
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
NCT06637423· Phase 1/2· Source
Terminated
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591· Phase 1· Source
Terminated
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT06568692· Phase 2· Source
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· Phase 3· Source
Completed
Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients
NCT06385587· Source
Completed
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
NCT06378047· Phase 1· Source
Completed
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT06188559· Phase 2· Source
Completed
Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
NCT06323291· Early phase 1· Source
Completed
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT06236425· Phase 1· Source
Terminated
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06128044· Phase 1· Source
Completed
Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study
NCT07101861· Source
Completed
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
NCT06234488· Source
Terminated
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694· Phase 3· Source
Completed
Study of DF6215 in Patients With Advanced Solid Tumors
NCT06108479· Phase 1· Source
Terminated
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133· Phase 1· Source
Completed
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
NCT06129422· Phase 1· Source
Terminated
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
NCT05756907· Phase 1/2· Source
Completed
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
NCT06050395· Source
Completed
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
NCT05510908· Source
Recruiting
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607· Phase 2· Source
Terminated
JSP191 (briquilimab) in Subjects with LR-MDS
NCT05903274· Phase 1· Source
Completed
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
NCT05704933· Early phase 1· Source
Completed
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
NCT05873439· Early phase 1· Source
Completed
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
NCT05712356· Phase 2· Source
Completed
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
NCT05798780· Source
Completed
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
NCT05763563· Source
Completed
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT05694364· Phase 1· Source
Terminated
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05576077· Phase 1· Source
Completed
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
NCT05675059· Source
Completed
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT05628883· Phase 1· Source
Completed
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113· Phase 2· Source
Completed
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
NCT05524545· Phase 1· Source
Terminated
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
NCT05375084· Phase 1· Source
Completed
Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy
NCT05579847· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Source
Completed
Nirogacestat in Ovarian Granulosa Cell Tumors
NCT05348356· Phase 2· Source
Completed
Exploring Men s Prostate Cancer Genetic Risk Perceptions
NCT06764992· Source
Completed
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812· Phase 1· Source
Completed
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
NCT05383872· Source
Withdrawn
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
NCT05364645· Phase 2· Source
Completed
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
NCT05444530· Phase 1· Source
Completed
Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
NCT05438927· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Source
Completed
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
NCT05360680· Phase 1· Source
Completed
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423· Phase 3· Source
Terminated
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
NCT05062980· Phase 1· Source
Completed
Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue
NCT04972097· Source
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439· Phase 1· Source

Showing 50 of 204.

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 01xf75524 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Moffitt Cancer Center: trials and research groups – Frontlight Research